Nebius AI Discovery Awards 2026 for AI Startups in Biopharma, Genomics, Digital Health, Medical Devices and Medical Imaging

The Nebius AI Discovery Awards are a compute-credit competition rather than a research grant, and the distinction matters for who should pursue them: awards are paid in GPU cloud credits on Nebius infrastructure, not cash, which makes them valuable to teams whose bottleneck is training and inference capacity and largely irrelevant to teams needing salary or equipment support.

The program is organized into five health-focused categories - BioPharma covering drug discovery and computational biology, Genomics covering sequencing analysis and variant detection, Digital Health covering clinical workflows and patient interaction, Medical Devices covering real-time AI and connected equipment, and Medical Imaging covering radiology, pathology and image analysis - with first, second and third place awards of $100,000, $50,000 and $30,000 in credits per category, plus seven honorable mentions.

The eligibility profile is commercial rather than academic: applicants must be startups with a legal entity, a functioning website, a product MVP and a go-to-market strategy, and may be bootstrapped, self-funded or venture-funded at any stage from pre-seed through Series D. Products using personal data must ensure anonymization, a meaningful constraint in these categories.

The scale of the 2026 round gives a sense of the competition - 646 submissions, of which 198 advanced to the semifinal before a final jury evaluation.

The May 8, 2026 deadline for this round has passed, but the category structure and eligibility criteria are a good guide for health-AI startups planning against a subsequent cycle, and compute-credit programs of this kind have become a meaningful funding channel for early-stage teams that cannot yet justify committed cloud spend.